custirsen
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic…
Purpose of review Multiple agents with very distinct mechanisms of actions and unique toxicities and efficacies have become…
222 Background: Durable pain palliation (dPP) in metastatic castrate-resistant prostate cancer (mCRPC) is a measure of clinical…
TPS5103 Background: Custirsen enhances chemotherapeutic activity via inhibition of clusterin expression. Clusterin is a…
TPS180 Background: Custirsen (OGX-011) is a second generation antisense oligonucleotide (ASO) with a prolonged tissue half-life…
Purpose of reviewPatients with metastatic castration-resistant prostate cancer (CRPC) no longer responsive to docetaxel have a…
Advances in prostate cancer therapies are shifting from a focus on cancer epithelial cells to targeting the tumor environment. In…